Rapport Therapeutics (NASDAQ:RAPP) Shares Down 6.5% - Time to Sell?

Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) shares fell 6.5% during mid-day trading on Friday . The company traded as low as $20.56 and last traded at $20.56. 5,964 shares changed hands during trading, a decline of 96% from the average session volume of 157,690 shares. The stock had previously closed at $21.98.

Rapport Therapeutics Price Performance

The firm has a 50-day moving average of $22.56.

Institutional Trading of Rapport Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. TD Asset Management Inc acquired a new position in shares of Rapport Therapeutics during the second quarter worth about $2,361,000. Johnson & Johnson bought a new stake in Rapport Therapeutics during the 2nd quarter valued at $58,105,000. Sofinnova Investments Inc. bought a new position in shares of Rapport Therapeutics in the second quarter valued at approximately $45,393,000. Davidson Kempner Capital Management LP bought a new position in Rapport Therapeutics during the second quarter valued at about $229,000. Finally, ARCH Venture Management LLC bought a new stake in Rapport Therapeutics during the second quarter worth approximately $86,730,000.

Rapport Therapeutics Company Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.